

Bleeding Disorder Patient Referral Form

Patient Demographics Information

Patient Name		SSN#	DOB
Patient Address			
Primary Phone	Cellular Phone	Work Phone	
Emergency Contact Name, Relationship		Emergency Contact Phone Number	

Additional Documentation Needed

- | | | |
|-------------------------------------|------------------------|----------------------|
| - Copy of insurance cards | - Baseline labs | - Inhibitor activity |
| - Patient face sheet w/demographics | - History and Physical | - Medication list |

Patient Insurance Information

Insurance Plan #1		Insurance Plan #2	
Subscriber Name	DOB	Subscriber Name	DOB
Policy Number	Group ID	Policy Number	Group ID

Patient Clinical Information

Gender ☐ M ☐ F	Height (inches)	Weight (lbs)	Allergies (food/drug)
---	-----------------	--------------	-----------------------

Primary Diagnosis & Access Information

ICD10: _____ Primary Diagnosis - Description: _____			
Date of diagnosis:	Circulating Factor:	Target Joint(s):	
Severity: ☐ Severe (<1%) ☐ Moderate (1-5%) ☐ Mild (>5%)		Inhibitor Activity: ☐ None ☐ Historical ☐ Current: _____ BU/mL	
Line Access Information: ☐ Peripheral Butterfly ☐ PICC ☐ Port ☐ Subcutaneous			

Medication Information / Prescription and Orders

Factor VIIa (Recombinant)	☐ NovoSeven RT ☐ SevenFact
Factor VIII (Recombinant)	☐ Advate ☐ Adynovate ☐ Altuviiro ☐ Afstyla ☐ Eloctate ☐ Esperoct ☐ Kovaltry ☐ Jivi ☐ NovoEight ☐ Nuwiq ☐ Recombinate ☐ Xyntha
Factor VIII (Human)	☐ Hemofil M ☐ Koate - DVI
Factor VIII Concentrate (Human)	☐ Corifact
Factor VIII (Human) + VWF	☐ Alphanate ☐ Humate-P ☐ Wilate
VWF (Recombinant)	☐ VonVendi
Factor IX (Recombinant)	☐ Alprolix ☐ Benefix ☐ Idelvion ☐ Ixinity ☐ Rixubis ☐ Rebinyn
Factor IX (Human)	☐ AlphaNine SD
Factor X (Human)	☐ Coagadex
Factor XIII A-Subunit (Recombinant)	☐ Tretten
Monoclonal Antibody (Recombinant)	☐ Hemlibra
Anti-Inhibitor (Human)	☐ Feiba
Pro-Thrombin Complex (Human)	☐ Profilnine SD
Antithrombin-directed siRNA	☐ Qfitlia
Anti-tissue Factor Pathway Inhibitor	☐ Alhemo ☐ Hympavzi
Other Regimen	☐ Amicar ☐ DDAVP ☐ Tranexamic Acid ☐ Other _____

Therapy Regimen for Factor or Inhibitor Products	☐ Prophylaxis _____ IU/mg _____/week
	☐ Breakthrough Bleed ☐ Mild: _____ IU ☐ Moderate: _____ IU ☐ Severe: _____ IU
	☐ Immune Tolerance Dose: _____ IU
	☐ Other Regimen Dose: _____ IU

Prescriber Information

Physician Name		Office Contact	
Practice Address		Practice Phone	
NPI#	License #	DEA#	
Physician Signature Required - Substitution Permitted		Date	Physician Signature Required - Dispense as Written
			Date